Corporate News Report
Cencora Inc. has announced that the results of a recently conducted randomized trial, evaluating its subcutaneous diuretic therapy for heart‑failure patients, have been published in a leading cardiovascular journal. The study, carried out across twenty hospitals in the United Kingdom, compared at‑home administration of a furosemide device to conventional inpatient intravenous treatment. Participants were able to self‑administer the medication at home with a wearable pump, achieving diuresis comparable to that obtained in hospital settings while reducing the number of days spent in inpatient care.
The trial met its primary objective of decreasing inpatient days, with participants receiving a total dose of furosemide that matched typical hospital regimens. Safety findings indicated that the at‑home approach produced similar rates of serious adverse events to the inpatient group, and device‑related complications were minimal. The data suggest that early discharge supported by a subcutaneous formulation may enable patients to spend more time outside the hospital without compromising clinical outcomes.
Cencora’s product, available through various distributors, is a drug‑device combination that delivers a high‑concentration furosemide formulation over a five‑hour period via a low‑profile infusion system. The device has been approved in the United States and is marketed for the treatment of edema in adults with chronic heart failure, a condition that traditionally requires intravenous therapy.
The company highlighted that its approach offers potential benefits for patients, payors, and healthcare providers by enabling self‑administration of an effective diuretic at home. While the announcement focuses on the clinical trial results, it also references the broader context of the company’s strategy to expand at‑home treatment options for conditions that are typically managed in hospital environments.
